3SBio Inc. (TRSBF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
3SBio Inc. (TRSBF) trades at $2.15 with AI Score 52/100 (Grade B). 3SBio Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing innovative products, primarily in China. Market cap: $5.38B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for TRSBF: TRSBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TRSBF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TRSBF: 1/3 scored disciplines lean bullish. Dominant signal: Moon AI bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
3SBio Inc. (TRSBF) Healthcare & Pipeline Overview
3SBio Inc. is a biopharmaceutical company focused on developing, producing, and marketing biopharmaceutical products in China and internationally. Its diverse portfolio includes treatments for oncology, hematology, nephrology, and dermatology, positioning it as a key player in the Chinese biopharmaceutical market with a focus on addressing unmet medical needs.
What Is the Investment Thesis for TRSBF?
3SBio Inc. presents a notable research candidate due to its established presence in the Chinese biopharmaceutical market and a diverse product portfolio. The company's strong gross margin of 85.4% and a return on equity of 14.0% indicate efficient operations and profitability. Growth catalysts include the expansion of its product pipeline and increasing demand for biopharmaceuticals in China. However, investors should be aware of the risks associated with operating in a highly regulated industry and the potential for competition from both domestic and international players. The company's debt-to-equity ratio of 9.88 suggests a conservative capital structure.
Based on FMP financials and quantitative analysis
TRSBF Key Highlights
Market capitalization of $5.38B reflects its established position in the biopharmaceutical market.
- Profit margin of 26.0% demonstrates strong profitability and efficient cost management.
- Gross margin of 85.4% indicates a strong pricing power and efficient production processes.
- Return on Equity (ROE) of 14.0% showcases the company's ability to generate profits from shareholders' investments.
- Debt-to-Equity ratio of 9.88 suggests a conservative capital structure and manageable debt levels.
Who Are TRSBF's Competitors?
TRSBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| BIIB Biogen Inc. | $217.35 | -1.90% | $32.1B | 64 |
| LGND Ligand Pharmaceuticals Incorporated | $287.39 | -1.14% | $5.76B | 94 |
| ACAD ACADIA Pharmaceuticals Inc. | $29.15 | -3.51% | $4.99B | 89 |
| LQDA Liquidia Corporation | $71.05 | -5.68% | $6.32B | 99 |
| ORKA Oruka Therapeutics, Inc. | $104.86 | -4.40% | $6.32B | 75 |
| CAI Caris Life Sciences, Inc. | $22.76 | +8.54% | $6.43B | 87 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TRSBF's Key Strengths?
Strong market position in China.
- Diverse product portfolio.
- Established manufacturing capabilities.
- High gross margin.
What Are TRSBF's Weaknesses?
Reliance on the Chinese market.
- Limited international presence.
- Exposure to regulatory risks.
- Dependence on key products.
What Could Drive TRSBF Stock Higher?
Regulatory approvals for new drug candidates in the pipeline.
- Expansion of sales and marketing efforts in China.
- Strategic partnerships and collaborations with other companies.
- Clinical trial results for key drug candidates.
- Increasing demand for biopharmaceuticals in China.
What Are the Key Risks for TRSBF?
Regulatory changes and compliance requirements.
- Pricing pressures and reimbursement challenges.
- Intense competition from domestic and international players.
- Intellectual property risks.
- Reliance on the Chinese market.
What Are the Growth Opportunities for TRSBF?
- Expanding product pipeline: 3SBio can drive growth by investing in the research and development of new biopharmaceutical products. Focusing on innovative therapies and addressing unmet medical needs in areas such as oncology and immunology can lead to significant revenue growth. The global oncology market is projected to reach $286.6 billion by 2030, presenting a substantial opportunity for 3SBio to capitalize on with its pipeline of oncology drugs. Timeline: Ongoing.
- Geographic expansion: 3SBio can expand its presence in international markets, particularly in Southeast Asia and other emerging economies. Leveraging its existing product portfolio and establishing strategic partnerships can facilitate market entry and drive revenue growth. The biopharmaceutical market in Southeast Asia is expected to grow at a CAGR of 9.8% from 2024 to 2029, offering a significant opportunity for 3SBio. Timeline: 2-3 years.
- Strategic acquisitions: 3SBio can pursue strategic acquisitions of complementary businesses or technologies to expand its product portfolio and enhance its capabilities. Acquiring companies with innovative drug candidates or advanced manufacturing technologies can accelerate growth and create synergies. The biopharmaceutical M&A market is expected to remain active, with opportunities for companies like 3SBio to acquire valuable assets. Timeline: Ongoing.
- Increased market penetration: 3SBio can increase its market share in China by expanding its sales and marketing efforts, strengthening its distribution network, and enhancing its brand awareness. Focusing on key regions and customer segments can drive revenue growth and improve profitability. Timeline: Ongoing.
- Development of biosimilars: 3SBio can capitalize on the growing market for biosimilars by developing and commercializing biosimilar versions of existing biologic drugs. Biosimilars offer a cost-effective alternative to branded biologics and can generate significant revenue. Timeline: 3-5 years.
What Are TRSBF's Competitive Advantages?
- Established presence in the Chinese biopharmaceutical market.
- Diverse product portfolio addressing multiple therapeutic areas.
- Strong manufacturing capabilities and quality control.
- Extensive distribution network in China.
What Does TRSBF Do?
Founded in 1993 and headquartered in Shenyang, China, 3SBio Inc. has evolved into a prominent biopharmaceutical company dedicated to improving the quality of life for patients. The company develops, manufactures, and markets a range of biopharmaceutical products, addressing critical therapeutic areas such as oncology, hematology, nephrology, auto-immune, ophthalmology, dermatology, and metabolism. 3SBio’s product portfolio includes TPIAO, a recombinant human thrombopoietin used to treat chemotherapy-induced thrombopenia and immune thrombocytopenia, and Yisaipu, a receptor fusion tumor necrosis factor inhibitor. Additionally, the company offers Cipterbin, an anti-HER2 monoclonal antibody for HER2-positive breast cancer, and EPIAO and SEPO, erythropoietin injections. Beyond pharmaceuticals, 3SBio also markets Mandi-minoxidil, an OTC treatment for hair loss, and SPARIN, an injectable low-molecular-weight heparin calcium. The company is also involved in research and development, trading, and the retail of pharmaceuticals, along with providing various services like project management, technology consultation, and financial advisory services. 3SBio's commitment to innovation and patient care has solidified its position in the biopharmaceutical industry.
What Products and Services Does TRSBF Offer?
- Develops and produces biopharmaceutical products.
- Markets and sells biopharmaceutical products in Mainland China and internationally.
- Offers treatments for chemotherapy-induced thrombopenia and immune thrombocytopenia.
- Provides anti-HER2 monoclonal antibody for advanced HER2-positive breast cancer.
- Manufactures erythropoietin injections.
- Sells OTC external medicine for treating hair loss.
- Engages in research and development of biotechnology and drugs.
How Does TRSBF Make Money?
- Develops and manufactures biopharmaceutical products.
- Markets and sells products directly to hospitals and pharmacies.
- Generates revenue through product sales in China and international markets.
- Invests in research and development to expand its product pipeline.
What Industry Does TRSBF Operate In?
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative therapies and advancements in drug development technologies. The Chinese biopharmaceutical market, in particular, is expanding due to a growing aging population and rising healthcare expenditure. 3SBio Inc. operates in a competitive landscape with both domestic and international players. The company's focus on key therapeutic areas and its established distribution network in China provide a competitive advantage. The industry is subject to stringent regulatory requirements and pricing pressures, which can impact profitability.
Who Are TRSBF's Key Customers?
- Hospitals and medical institutions in China.
- Pharmacies and drug stores.
- Patients requiring treatments for various diseases.
- International distributors and partners.
3SBio Inc. (TRSBF) Valuation Context
Valued at $5.38B, TRSBF is classified as a mid-cap stock. Relative to its peer group, TRSBF's quantitative score of 52/100 is below the peer average of 79/100.
TRSBF Revenue & Earnings Trend
In Q4 2025, TRSBF generated $13.12B in top-line revenue, marking a sequential increase of 201.2%. The company recorded net income of $7.01B, with diluted EPS of $2.87. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, TRSBF averaged $1.07 in diluted EPS.
Company Profile
3SBio Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Shenyang, CN. The company is led by CEO Jing Lou. TRSBF has traded publicly since 2018.
Key Financial Metrics
Return on equity for 3SBio Inc. stands at 39.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 23.4%, showing how much profit it generates from its asset base. TRSBF trades at a trailing price-to-earnings ratio of 4.43, below the Healthcare sector average of ~23x. Its free cash flow yield is 24.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 22.6%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
3SBio Inc.'s Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 6.98 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
3SBio Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.6% below estimates on average.
Forward Outlook
Wall Street analysts project 3SBio Inc. revenue of about $10.06B for fiscal 2026, with EPS near $1.04. The estimate reflects 11 contributing analysts.
TRSBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market position in China.
- Diverse product portfolio.
- Established manufacturing capabilities.
- High gross margin.
Bear Case
- Reliance on the Chinese market.
- Limited international presence.
- Exposure to regulatory risks.
- Dependence on key products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $13.12B | $7.01B | $2.87 |
| Q2 2025 | $4.36B | $1.36B | $0.56 |
| Q4 2024 | $4.72B | $1.00B | $0.40 |
| Q2 2024 | $4.39B | $1.09B | $0.45 |
Based on FMP financials and quantitative analysis
TRSBF Latest News
No recent news available for TRSBF.
TRSBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TRSBF.
Price Targets
Wall Street price target analysis for TRSBF.
TRSBF MoonshotScore
What does this score mean?
The MoonshotScore rates TRSBF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
TRSBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that 3SBio Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited trading volume and higher risk profiles.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Higher bid-ask spreads increase transaction costs.
- Potential for delisting or suspension of trading.
- Increased risk of fraud or manipulation.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price movements.
- Consult with a financial advisor.
- Established business operations in China.
- Presence in the biopharmaceutical industry.
- Product portfolio addressing multiple therapeutic areas.
- Market capitalization above $5 billion.
- History of developing and commercializing biopharmaceutical products.
3SBio Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for TRSBF?
TRSBF holds an AI Score of 52/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. 3SBio Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing innovative products, primarily in China. The company's portfolio addresses therapeutic areas including …
What does 3SBio Inc. do?
3SBio Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapies, primarily in China. The company's product portfolio addresses a range of therapeutic areas, including oncology, hematology, nephrology, and dermatology. 3SBio's key products include TPIAO, Yisaipu, and EPIAO, which are used to treat various conditions such as thrombocytopenia, rheumatoid arthritis, and anemia.
What are the main risks for TRSBF?
The main risks for 3SBio Inc. include regulatory risks, competition, pricing pressures, and intellectual property risks. The biopharmaceutical industry is subject to stringent regulatory requirements, and delays in obtaining regulatory approvals can impact the company's ability to commercialize its products.
What are the key factors to evaluate for TRSBF?
3SBio Inc. (TRSBF) holds an AI score of 52/100 (moderate). presents a notable research candidate due to its established presence in the Chinese biopharmaceutical market and a diverse product portfolio. Not financial advice.
How frequently does TRSBF data refresh on this page?
TRSBF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TRSBF's recent stock price performance?
3SBio Inc. (TRSBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRSBF overvalued or undervalued right now?
3SBio Inc. (TRSBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TRSBF before investing?
Before investing in 3SBio Inc. (TRSBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding TRSBF to a portfolio?
Key strength of 3SBio Inc. (TRSBF): Strong market position in China. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for TRSBF.